14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CFLT vs PATH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Confluent, Inc. (CFLT) captures the overall head-to-head institutional edge over UiPath, Inc. (PATH) on higher Unified Composite conviction (62.8/100 BUY vs. 58.3/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PATH wins 4–2 across the 6-pillar growth and valuation breakdown. CFLT trades at $30.99 (46.7x Forward P/E, -27.5% operating margin) versus PATH at $13.24 (17.4x Forward P/E, 9.4% operating margin).
Growth vs. Quality Trade-Off: CFLT earns the overall head-to-head edge with a stronger Unified Composite Score (62.8/100 BUY vs. PATH 58.3/100 HOLD) and 0.99β · 4% Vol risk profile, whereas PATH leads top-line expansion (+13.4% YoY revenue growth, 0.41x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CFLT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.9); meanwhile PATH is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CFLT vs PATH. Trailing 12-month operating profitability (CFLT -27.5% vs PATH 9.4%) and valuation multiples (CFLT 46.7x vs PATH 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Software - Infrastructure value chain with $6.8B market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment73.2% of Rev ($1.26B)
90D Engineering Disclosures0 Published
Investor FAQ CFLT vs PATH Key Questions & Quantitative Answers
As of Nov 16, 2026, Confluent, Inc. (CFLT) captures the overall head-to-head institutional edge over UiPath, Inc. (PATH) on higher Unified Composite conviction (62.8/100 BUY vs. 58.3/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PATH wins 4–2 across the 6-pillar growth and valuation breakdown. CFLT trades at $30.99 (46.7x Forward P/E, -27.5% operating margin) versus PATH at $13.24 (17.4x Forward P/E, 9.4% operating margin). Growth vs. Quality Trade-Off: CFLT earns the overall head-to-head edge with a stronger Unified Composite Score (62.8/100 BUY vs. PATH 58.3/100 HOLD) and 0.99β · 4% Vol risk profile, whereas PATH leads top-line expansion (+13.4% YoY revenue growth, 0.41x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CFLT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.9); meanwhile PATH is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CFLT leads the Growth & Scale pillar: CFLT posts +20.5% YoY revenue growth and +0.0% YoY earnings growth on $1.17B TTM revenue (74.3% gross margin, -27.5% operating margin), compared with PATH at +13.4% YoY revenue growth and N/A YoY earnings growth on $1.72B TTM revenue (82.6% gross margin, 9.4% operating margin). On trailing 12-month operating scale, CFLT generates $1.17B in USD-normalized revenue versus $1.72B for PATH. In operating R&D and SG&A reinvestment, CFLT deploys N/A (0 90-day corporate R&D disclosures) versus 73.2% of Rev ($1.26B) (0 disclosures) for PATH.
PATH screens cheaper on headline valuation multiples. CFLT trades at 46.7x Forward P/E, 61.4x Trailing P/E, 2.16x PEG, and 9.4x EV/Revenue (-29.0% EBITDA margin), whereas PATH trades at 17.4x Forward P/E, 19.6x Trailing P/E, 0.41x PEG, and 3.7x EV/Revenue (21.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CFLT (-27.7% ROE) versus PATH (20.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CFLT carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.99β · 4% Vol realized risk). By comparison, PATH carries 50.3% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.